Abstract
Historically, systemic therapies for advanced, metastatic thyroid carcinomas have been poorly effective. However, as a result of a confluence of increasing knowledge of the biologic basis for thyroid cancer development and progression, identification of therapeutic agents that could target these biologic abnormalities, and enthusiasm for research by both funding agencies as well as patients, multiple clinical trials have been initiated and successfully completed during the past several years. This article focuses on findings from key studies that reflect the new paradigms for treatment.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Axitinib
-
Benzamides
-
Benzenesulfonates / therapeutic use
-
Carcinoma / therapy*
-
Clinical Trials as Topic / trends*
-
Drug Delivery Systems / methods
-
Drug Delivery Systems / trends
-
Gefitinib
-
Humans
-
Imatinib Mesylate
-
Imidazoles / therapeutic use
-
Indazoles / therapeutic use
-
Indoles / therapeutic use
-
Niacinamide / analogs & derivatives
-
Niacinamide / therapeutic use
-
Oligonucleotides
-
Phenylurea Compounds
-
Piperazines / therapeutic use
-
Piperidines / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use
-
Pyridines / therapeutic use
-
Pyrimidines / therapeutic use
-
Quinazolines / therapeutic use
-
Sorafenib
-
Thyroid Neoplasms / therapy*
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Benzamides
-
Benzenesulfonates
-
Imidazoles
-
Indazoles
-
Indoles
-
Oligonucleotides
-
Phenylurea Compounds
-
Piperazines
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyridines
-
Pyrimidines
-
Quinazolines
-
Niacinamide
-
Imatinib Mesylate
-
Sorafenib
-
Axitinib
-
imetelstat
-
Gefitinib
-
vandetanib